Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

COUCH Medcomms

- PMLiVE

Eisai and Washington University to develop neurodegenerative disease therapies

Alzheimer’s will be a central focus for the new drug discovery collaboration

- PMLiVE

Boehringer’s Spevigo receives EC approval for generalised pustular psoriasis flares

Trial showed 54% of patients were free of pustules one week after a single dose

- PMLiVE

UCB’s Epicensus programme highlights need to address psoriasis care gap

The programme was published in Dermatology and Therapy

- PMLiVE

Assessing the impact of rarity on French HTA and pricing decisions

With changes to the pricing and access processes such as the new Accord Cadre and the soon-to-be implemented ATU reform likely to impact pricing and access of orphan products in...

How to Increase Engagement During Virtual Events

Tip #4 - How do you plan the agenda for your virtual event? We suggest to invite participant input to build and personalize the engagement. Check out our full top...

Impetus Digital

- PMLiVE

Sanofi and Regeneron’s Dupixent granted EC approval for prurigo nodularis

Two phase 3 trials showed a reduction in itch, skin lesions and health-related quality of life

- PMLiVE

Novartis’ iptacopan shows promise as rare blood disease treatment in phase 3 study

Around 82.3% of patients achieved haemoglobin-level increases of 2g/dL or more from baseline

- PMLiVE

Eli Lilly and EVA Pharma collaborate to enhance insulin access in Africa

The African-made insulin products are expected to reach one million people per year by 2030

- PMLiVE

Genomics England receives government funding for cutting-edge genomics research

£105m will be used to accelerate the diagnosis of rare genetic diseases in newborns

- PMLiVE

ICR and University of Cambridge reveal new prostate cancer prediction tool

The new study describing the model is published in the Journal of Clinical Oncology

- PMLiVE

Creative destruction

Biotech’s problems create opportunities for others

- PMLiVE

Merck and Moderna’s personalised cancer vaccine shows promise in high-risk melanoma patients

The vaccine in combination with Keytruda reduced the risk of recurrence or death by 44%

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links